Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 601–700 of 1,003

Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways
Tao, Y., Han, T., Zhang, T., & Sun, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.017 · Cited by 33
Genetic and epigenetic markers in colorectal cancer screening: recent advances
Singh, M. P., Rai, S., Suyal, S., Singh, S. K., Singh, S. K., Agarwal, A., & Srivastava, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1337511 · Cited by 30
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
Procaccio, L., Damuzzo, V., Sarra, F. D., Russi, A., Todino, F., Dadduzio, V., Bergamo, F., Prete, A. A., Lonardi, S., Prenen, H., et al. (2019) · Drug Safety · doi:10.1007/s40264-018-0776-6 · Cited by 30
Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation
Gilson, P., Franczak, C., Dubouis, L., Husson, M., Rouyer, M., Demange, J., Perceau, M., Leroux, A., Merlin, J., & Harlé, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219204 · Cited by 30
Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer
Nakamura, H., Takada, K., Arihara, Y., Hayasaka, N., Murase, K., Iyama, S., Kobune, M., Miyanishi, K., & Kato, J. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0056-8 · Cited by 29
Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto
Hashimoto, D., Satoi, S., Fujii, T., Sho, M., He, J. P., Hackert, T., Chiaro, M. D., Jang, J., Gulla, A., Yoon, Y., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.07.005 · Cited by 29
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 30
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Vidal, J., Bellosillo, B., Vivas, C. S., Alfonso, P. G., Carrato, A., Cano, M. T., García‐Carbonero, R., Élez, E., Losa, F., Massutí, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz005 · Cited by 28
Self-citation
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial
Bachet, J., Lucidarme, O., Levaché, C.-B., Barbier, E., Raoul, J., Lecomte, T., Desauw, C., Brocard, F., Pernot, S., Breysacher, G., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.006 · Cited by 29
Self-citation
A UGT1A1 genotype‐guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
Sharma, M. R., Joshi, S. S., Karrison, T. G., Allen, K., Suh, G. K., Marsh, R., Kozloff, M. F., Polite, B. N., Catenacci, D. V. T., & Kindler, H. L. (2019) · Cancer · doi:10.1002/cncr.31938 · Cited by 29
Impact of CEA-targeting Nanoparticles for Drug Delivery in Colorectal Cancer
Sousa, A. R., Oliveira, M. J., & Sarmento, B. F. C. C. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254441 · Cited by 29
Value of Tumor Size as a Prognostic Factor In Metastatic Colorectal Cancer Patients After Chemotherapy: A Population-Based Study
Yan, Q., Zhang, K., Guo, K., Liu, S., Wasan, H. S., Jin, H., Li, Y., Guan, F., Shen, F., Shen, M., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0785 · Cited by 29
Self-citation
Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
Li, S., Dong, D., Geng, J., Zhu, X., Chen, S., Zhang, Y., Wang, H., Zhou, S., Wu, H., Cai, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01080 · Cited by 29
Lycorine induces autophagy-associated apoptosis by targeting MEK2 and enhances vemurafenib activity in colorectal cancer
Hu, M., Yu, Z., Mei, P., Li, J., Luo, D., Zhang, H., Zhou, M., Liang, F., & Chen, R. (2020) · Aging · doi:10.18632/aging.102606 · Cited by 28
Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
Aparicio, T., Canouï‐Poitrine, F., Caillet, P., François, É., Cudennec, T., Carola, É., Albrand, G., Bouvier, A., Petri, C., Couturier, B., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.12.145 · Cited by 29
Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study
van Roekel, C., van den Hoven, A. F., Bastiaannet, R., Bruijnen, R. C. G., Braat, A. J. A. T., de Keizer, B., Lam, M. G. E. H., & Smits, M. L. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05079-0 · Cited by 29
Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
Oki, E., Makiyama, A., Miyamoto, Y., Kotaka, M., Kawanaka, H., Miwa, K., Kabashima, A., Noguchi, T., Yuge, K., Kashiwada, T., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3618 · Cited by 31
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database
Uhlig, J., Cecchini, M., Sheth, A. H., Stein, S., Lacy, J., & Kim, H. S. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7619 · Cited by 29
Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer
Froelich, M. F., Schnitzer, M. L., Rathmann, N., Tollens, F., Unterrainer, M., Rennebaum, S., Seidensticker, M., Ricke, J., Rübenthaler, J., & Kunz, W. G. (2021) · Cancers · doi:10.3390/cancers13071507 · Cited by 29
Self-citation
Liquid biopsy genotyping by a simple lateral flow strip assay with visual detection
Kalligosfyri, P. M., Nikou, S., Bravou, V., & Kalogianni, D. P. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338470 · Cited by 29
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
Qin, S., Li, J., Bai, Y., Shu, Y., Li, W., Yin, X., Cheng, Y., Sun, G., Deng, Y., Zhong, H., et al. (2021) · BioDrugs · doi:10.1007/s40259-021-00484-9 · Cited by 29
Percutaneous electrochemotherapy in primary and secondary liver malignancies – local tumor control and impact on overall survival
Spallek, H., Bischoff, P., Zhou, W., de Terlizzi, F., Jakob, F., & Kovács, A. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0003 · Cited by 29
Management of single pulmonary metastases from colorectal cancer: State of the art
Chiappetta, M., Salvatore, L., Congedo, M. T., Bensi, M., Luca, V. D., Ciavarella, L. P., Camarda, F., Evangelista, J., Valentini, V., Tortora, G., et al. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i4.820 · Cited by 29
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study
Mentrasti, G., Cantini, L., Zichi, C., D’Ostilio, N., Gelsomino, F., Martinelli, E., Chiari, R., Verde, N. M. L., Bisonni, R., Cognigni, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac129 · Cited by 32
Gut microbiome in tumorigenesis and therapy of colorectal cancer
Wang, L., Yu, K., Hou, Y., Guo, M., Yao, F., & Chen, Z. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30917 · Cited by 31
Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer
Han, T., Lin, J., Wang, Y., Fan, Q., Sun, H., Tao, Y., & Sun, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.190 · Cited by 29
Long-Term Outcomes in Percutaneous Radiofrequency Ablation for Histologically Proven Colorectal Lung Metastasis
Zhong, J., Palkhi, E., Ng, H. H. L., Wang, K., Milton, R. S., Chaudhuri, N., Lenton, J., Smith, J. T., Bhartia, B., & Wah, T. M. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02623-1 · Cited by 29
Colorectal cancer cells establish metabolic reprogramming with cancer-associated fibroblasts (CAFs) through lactate shuttle to enhance invasion, migration, and angiogenesis
Wang, X. T., Qu, Y., Ji, J., Liu, H., Luo, H., Li, J., & Han, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113470 · Cited by 30
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
Quidde, J., Hegewisch‐Becker, S., Graeven, U., Lerchenmuller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw425 · Cited by 28
Self-citation
Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer—Predictive Factors and Prognosis
Nozawa, H., Ishihara, S., Kawai, K., Hata, K., Kiyomatsu, T., Tanaka, T., Nishikawa, T., Otani, K., Yasuda, K., Sasaki, K., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.002 · Cited by 28
Selecting treatment options in refractory metastatic colorectal cancer
Byrne, M. M., & Saif, M. W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194605 · Cited by 28
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Brunsell, T. H., Sveen, A., Bjørnbeth, B. A., Røsok, B. I., Danielsen, S. A., Brudvik, K. W., Berg, K. C. G., Johannessen, B., Cengija, V., Abildgaard, A., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.09.003 · Cited by 29
ADAMTS8 is frequently down-regulated in colorectal cancer and functions as a tumor suppressor
Li, L., Yuan, S., Zhao, X., & Luo, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.020 · Cited by 28
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion
Montés, A. F., Grávalos, C., Pericay, C., Safont, M. J., Benavides, M., Élez, E., Alfonso, P. G., García-Paredes, B., Carrato, A., & Aranda, E. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.003 · Cited by 28
miRNAs‐Based Molecular Signature for KRAS Mutated and Wild Type Colorectal Cancer: An Explorative Study
Milanesi, E., Dobre, M., Bucuroiu, I. A., Herlea, V., Manuc, T. E., Salvi, A., Petro, G. D., Mănuc, M., & Becheanu, G. (2020) · Journal of Immunology Research · doi:10.1155/2020/4927120 · Cited by 28
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Liu, Y., Lyu, J., Burdett, K. B., Sibley, A. B., Hatch, A. J., Starr, M. D., Brady, J. C., Hammond, K., Marmorino, F., Rossini, D., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0249 · Cited by 28
Self-citation
KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research
He, K., Wang, Y., Zhong, Y., Pan, X., Si, L., & Lu, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279312 · Cited by 28
Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer
Kanter, K. N., Fish, M., Mauri, G., Horick, N., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Ryan, D. P., Nipp, R. D., Giantonio, B. J., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.20.01010 · Cited by 28
Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses
Shi, Z., Zhu, X., Ke, S., Qiu, H., Cai, G., Zhangcai, Y., & Chen, Y. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.09.033 · Cited by 28
Emerging Therapeutic Agents for Colorectal Cancer
Nalli, M., Puxeddu, M., Regina, G. L., Gianni, S., & Silvestri, R. (2021) · Molecules · doi:10.3390/molecules26247463 · Cited by 29
Ablation versus resection for resectable colorectal liver metastases - Health care related cost and survival analyses from a quasi-randomised study
Tinguely, P., Laurell, G., Enander, A., Engstrand, J., & Freedman, J. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.09.006 · Cited by 28
Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
Ma, S., Chen, R., Duan, L., Li, C., Yang, T., Wang, J., & Da, Z. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-108 · Cited by 28
EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment
Gazzaniga, P., Raimondi, C., Urbano, F., & Cortesi, E. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00277 · Cited by 28
Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
Pan, J., Zhou, H. K., Zhu, S.-B., Huang, J.-L., Zhao, X.-X., Ding, H., & Pan, Y.-L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s170105 · Cited by 28
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
Yasuno, M., Uetake, H., Ishiguro, M., Mizunuma, N., Komori, T., Miyata, G., Shiomi, A., Kagimura, T., & Sugihara, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-01393-8 · Cited by 28
Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases—a Japanese Nationwide Survey
Kobayashi, S., Beppu, T., Honda, G., Yamamoto, M., Takahashi, K., Endo, I., Hasegawa, K., Kotake, K., Itabashi, M., Hashiguchi, Y., et al. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04250-9 · Cited by 28
KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy
Favazza, L. A., Parseghian, C. M., Kaya, C., Nikiforova, M. N., Roy, S., Wald, A. I., Landau, M. S., Proksell, S. S., Dueker, J. M., Johnston, E. R., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0560-x · Cited by 29
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
Cremolini, C., Antoniotti, C., Moretto, R., Masi, G., & Falcone, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.219 · Cited by 28
Self-citation
Comparative Effects of Different Nutritional Supplements on Inflammation, Nutritional Status, and Clinical Outcomes in Colorectal Cancer Patients: A Systematic Review and Network Meta-Analysis
Ye, J., Hu, Y., Chen, X., Chang, C., & Li, K. (2023) · Nutrients · doi:10.3390/nu15122772 · Cited by 30
Irreversible electroporation of hepatocellular carcinoma and colorectal cancer liver metastases: A nationwide multicenter study with short- and long-term follow-up
Frühling, P., Stillström, D., Holmquist, F., Nilsson, A., & Freedman, J. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107046 · Cited by 27
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
Song, Y., Mao, Q., Zhou, M., Liu, C.-J., Kong, L., & Hu, T. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03134-w · Cited by 29
Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer
Shimada, Y., Kameyama, H., Nagahashi, M., Ichikawa, H., Muneoka, Y., Yagi, R., Tajima, Y., Okamura, T., Nakano, M., Sakata, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20510 · Cited by 27
Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions
Shimada, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Oyanagi, H., Okuda, S., Takabe, K., & Wakai, T. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.020 · Cited by 27
A Radiologist’s Point of View in the Presurgical and Intraoperative Setting of Colorectal Liver Metastases
Granata, V., Fusco, R., Avallone, A., Catalano, O., Piccirillo, M., Palaia, R., Nasti, G., Petrillo, A., & Izzo, F. (2018) · Future Oncology · doi:10.2217/fon-2018-0080 · Cited by 27
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial
Kosumi, K., Hamada, T., Zhang, S., Liu, L., da Silva, A., Koh, H., Twombly, T. S., Mima, K., Morikawa, T., Song, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.022 · Cited by 27
Sub-millimeter surgical margin is acceptable in patients with good tumor biology after liver resection for colorectal liver metastases
Xu, D., Wang, H., Yan, X., Li, J., Wang, K., & Xing, B. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.03.010 · Cited by 27
Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis
de’Angelis, N., Baldini, C., Brustia, R., Pessaux, P., Sommacale, D., Laurent, A., Roy, B. L., Tacher, V., Kobeiter, H., Luciani, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230914 · Cited by 27
Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease
Whelton, S. P., Berning, P., Blumenthal, R. S., Marshall, C. H., Martin, S. S., Mortensen, M. B., Blaha, M. J., & Dzaye, O. D. A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.02.003 · Cited by 27
Conversion therapy in patients with colorectal liver metastases
Villard, C., Habib, M., Nordenvall, C. A. M., Nilsson, P. J., Jorns, C., & Sparrelid, E. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.02.019 · Cited by 27
Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
Al-Salama, Z. T. (2021) · Drugs · doi:10.1007/s40265-021-01501-5 · Cited by 27
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
Mollà, M., Fernández-Plana, J., Albiol, S., Fondevila, C., Vollmer, I., Cases, C., García‐Criado, Á., Capdevila, J., Conill, C., Fundora, Y., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102131 · Cited by 29
Advanced Deep Learning Approach to Automatically Segment Malignant Tumors and Ablation Zone in the Liver With Contrast-Enhanced CT
He, K., Liu, X., Shahzad, R., Reimer, R. P., Thiele, F. O., Niehoff, J. H., Wybranski, C., Bunck, A. C., Zhang, H., & Perkuhn, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669437 · Cited by 29
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 27
Identification of CT Imaging Phenotypes of Colorectal Liver Metastases from Radiomics Signatures—Towards Assessment of Interlesional Tumor Heterogeneity
Tharmaseelan, H., Hertel, A., Tollens, F., Rink, J. S., Woźnicki, P., Haselmann, V., Ayx, I., Nörenberg, D., Schoenberg, S. O., & Froelich, M. F. (2022) · Cancers · doi:10.3390/cancers14071646 · Cited by 28
Distant Metastasis Pattern and Prognostic Prediction Model of Colorectal Cancer Patients Based on Big Data Mining
Liu, C., Wang, T., Yang, J., Zhang, J., Wei, S., Guo, Y., Yu, R., Tan, Z., Wang, S., & Dong, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878805 · Cited by 27
Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer
Hao, M., Wang, K., Ding, Y., Li, H., Liu, Y., & Ding, L. (2022) · European journal of medical research · doi:10.1186/s40001-022-00759-z · Cited by 30
Validation study of the JSHBPS nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era ‐ a nationwide survey in Japan
Beppu, T., Yamamura, K., Sakamoto, K., Honda, G., Kobayashi, S., Endo, I., Hasegawa, K., Kotake, K., Itabashi, M., Hashiguchi, Y., et al. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1256 · Cited by 27
A deep learning-based framework for predicting survival-associated groups in colon cancer by integrating multi-omics and clinical data
Salimy, S., Lanjanian, H., Abbasi, K., Salimi, M., Najafi, A., Tapak, L., & Masoudi‐Nejad, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17653 · Cited by 31
Fusobacterium nucleatum carcinogenesis and drug delivery interventions
Chen, Z., & Huang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115319 · Cited by 27
Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France
Loffroy, R., Ronot, M., Greget, M., Bouvier, A. A., Mastier, C., Sengel, C., Tselikas, L., Arnold, D., Maleux, G. A., Pelage, J., et al. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02643-x · Cited by 27
Self-citation
Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
Zoetemelk, M., Ramzy, G. M., Rausch, M., Koessler, T., B, J. R. V. B., Weiss, A., Mieville, V., Piersma, S. R., de Haas, R. R., Delucinge-Vivier, C., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12797 · Cited by 28
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies
Salvatore, L., Bria, E., Sperduti, I., Hinke, A., Hegewisch-Becker, S., Aparicio, T., Le Malicot, K., Boige, V., Koeberle, D., Baertschi, D., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102202 · Cited by 26
Self-citation
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Semira, C., Wong, H., Field, K. M., Lee, M., Lee, B., Nott, L. M., Shapiro, J. D., Wong, R., Tie, J., Tran, B., et al. (2018) · Internal Medicine Journal · doi:10.1111/imj.14115 · Cited by 27
Self-citation
Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases
Conrad, C. H., Vauthey, J., Masayuki, O., Sheth, R. A., Yamashita, S., Passot, G., Bailey, C. E., Zorzi, D., Kopetz, S., Aloia, T. A., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6089-7 · Cited by 26
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
Pastorino, A., Bartolomeo, M. D., Maiello, E., Iaffaioli, V. R., Ciuffreda, L., Fasola, G., Costanzo, F. D., Frassineti, G. L., Marchetti, P., Antoniotti, C., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.03.002 · Cited by 26
Self-citation
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
Kanat, Ö., & Ertaş, H. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i2.52 · Cited by 28
Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases
Allard, M., Nishioka, Y., Beghdadi, N., Imai, K., Gelli, M., Yamashita, S., Kitano, Y., Kokudo, T., Yamashita, Y., Cunha, A. S., et al. (2019) · BJS Open · doi:10.1002/bjs5.50174 · Cited by 26
Self-citation
FDG PET/CT in colorectal cancer
Rodríguez‐Fraile, M., Cozar, M., Sabaté-Llobera, A., Caresia-Aróztegui, A. P., Delgado-Bolton, R. C., Orcajo-Rincón, J., de Arcocha-Torres, M., García‐Velloso, M. J., & García-Talavera, P. (2019) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2019.12.001 · Cited by 26
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Rossini, D., Germani, M. M., Pagani, F., Pellino, A., Dell’Aquila, E., Bensi, M., Liscia, N., Moretto, R., Boccaccino, A., Prisciandaro, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.03.009 · Cited by 26
Self-citation
Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan
Kobayashi, S., Takahashi, S., Takahashi, N., Masuishi, T., Shoji, H., Shinozaki, E., Yamaguchi, T., Kojima, M., Gotohda, N., Nomura, S., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08817-8 · Cited by 27
Self-citation
Multimodal treatment strategies for colorectal liver metastases
Birrer, D. L., Tschuor, C., Reiner, C. S., Fritsch, R., Pfammatter, T., Schüler, H. I. G., Pavic, M., de Oliveira, M., Petrowsky, H., Dutkowski, P., et al. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20390 · Cited by 26
Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer
Budithi, A., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13112632 · Cited by 25
Expression and Prognostic Characteristics of Ferroptosis-Related Genes in Colon Cancer
Zhu, J., Kong, W., & Xie, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115652 · Cited by 26
Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy
Wei, S., Han, Y., Zeng, H., Ye, S., Cheng, J., Chai, F., Wei, J., Zhang, J., Hong, N., Bao, Y., et al. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109863 · Cited by 26
Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival – a registry-based study
Rollet, Q., Bouvier, V., Moutel, G., Launay, L., Bignon, A.-L., Bouhier‐Leporrier, K., Launoy, G. D., & Lièvre, A. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-07022-x · Cited by 26
Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer
Dias, D. D. S., Machado, M., Trabulo, C., Gosálbez, B., & Ravasco, P. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.671547 · Cited by 26
Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer
Makutani, Y., Kawakami, H., Tsujikawa, T., Yoshimura, K., Chiba, Y., Ito, A., Kawamura, J., Haratani, K., & Nakagawa, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956270 · Cited by 30
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
Lonardi, S., Nimeiri, H. S., Xu, C., Zollinger, D. R., Madison, R. W., Fine, A. D., Gjoerup, O. V., Rasola, C., Angerilli, V., Sharma, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911529 · Cited by 26
Percutanous Electrochemotherapy (ECT) in Primary and Secondary Liver Malignancies: A Systematic Review
Granata, V., Fusco, R., D’Alessio, V., Simonetti, I., Grassi, F., Silvestro, L., Palaia, R., Belli, A., Patrone, R., Piccirillo, M., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020209 · Cited by 26
Regorafenib in the Treatment of Metastatic Colorectal Cancer
de la Fouchardière, C. (2018) · Future Oncology · doi:10.2217/fon-2017-0512 · Cited by 26
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients
Milana, F., Famularo, S., Luberto, A., Rimassa, L., Scorsetti, M., Comito, T., Pressiani, T., Franzese, C., Poretti, D., Tommaso, L. D., et al. (2022) · Cancers · doi:10.3390/cancers14163952 · Cited by 25
Synthetic mismatches enable specific CRISPR-Cas12a-based detection of genome-wide SNVs tracked by ARTEMIS
Kohabir, K. A. V., Linthorst, J., Nooi, L. O., Brouwer, R., Wolthuis, R. M. F., & Sistermans, E. A. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100912 · Cited by 25
Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers
Fontanges, Q., Mendonça, R. D., Salmon, I. J., Mercier, M. L., & D’Haene, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122117 · Cited by 25
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer
Prieto‐Potín, I., Montagut, C. O., Bellosillo, B., Evans, M., Smith, M. R., Melchior, L. C., Werner, R., Bennett, M., Pennati, V., Castiglione, F., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.008 · Cited by 25
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
Argilés, G., Arnold, D., Prager, G. W., Sobrero, A. F., & Cutsem, E. V. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000495 · Cited by 25
Self-citation
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience
Narasimhan, V., Britto, M. M., Pham, T. D., Warrier, S. K., Naik, A., Lynch, A. C., Michael, M., Tie, J., Ramsay, R. G., & Heriot, A. G. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001456 · Cited by 25
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis
Schlicker, A., Ellappalayam, A., Beumer, I. J., Snel, M. H. J., Mittempergher, L., Diosdado, B., Dreezen, C., Tian, S., Salazar, R., Loupakis, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33003 · Cited by 25
Self-citation
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
Schimanski, C. C., Kasper, S., Hegewisch‐Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Bechstein, W. O., Vöhringer, M. C., Öllinger, R., Lordick, F., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1806680 · Cited by 25
Self-citation
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Stahler, A., Stintzing, S., Modest, D. P., Ricard, I., Gießen-Jung, C., Kapaun, C., Ivanova, B., Kaiser, F., von Weikersthal, L. F., Moosmann, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2748 · Cited by 26
Self-citation
The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients
Jacome, A. A. D. A., Vreeland, T. J., Johnson, B., Kawaguchi, Y., Wei, S. H., You, Y. N., Vilar, E., Vauthey, J., & Eng, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01169-w · Cited by 25

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks